Literature DB >> 17070313

Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer.

Ma'anit Shapira1, Ofer Ben-Izhak, Merav Slotky, Oleg Goldin, Shirly Lahav-Baratz, Dan D Hershko.   

Abstract

PURPOSE: Loss of the cell cycle inhibitory protein p27Kip1 in cancer is associated with tumor aggressiveness and poor prognosis in the prostate. The decrease in p27(Kip1) results from increased proteasome dependent degradation, which is mediated by its specific ubiquitin ligase subunits S-phase kinase protein 2 and cyclin dependent kinase subunit 1. S-phase kinase protein 2 was found to be over expressed in aggressive prostate cancers but to our knowledge the role of cyclin dependent kinase subunit 1 in these cancers is unknown.
MATERIALS AND METHODS: The expression of cyclin dependent kinase subunit 1, S-phase kinase protein 2 and p27Kip1 was examined by immunohistochemistry in tissue sections from 45 patients with prostate cancer. The expression of cyclin dependent kinase subunit 1 was compared to that of S-phase kinase protein 2 and p27Kip1, and patient clinical and histological characteristics.
RESULTS: Cyclin dependent kinase subunit 1 expression was strongly associated with S-phase kinase protein 2 expression (r = 0.666, p = 0.001) and inversely with p27Kip1 expression (r = -0.737, p < 0.001). Cyclin dependent kinase subunit 1 over expression was associated with loss of tumor differentiation (r = 0.631, p = 0.001), high serum prostate specific antigen (r = 0.627, p < 0.001) and metastatic disease (p < 0.001).
CONCLUSIONS: These results suggest that cyclin dependent kinase subunit 1 is involved in p27Kip1 down-regulation and it may have an important causative role in the development of aggressive tumor behavior in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070313     DOI: 10.1016/j.juro.2006.07.051

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Immunohistochemically detected expression of Skp2, p27 kip1, and p-p27 (Thr187) in patients with cholangiocarcinoma.

Authors:  Jian Luo; Yi Zhou; Bing Wang; Qiang Li; Yongjun Chen; Hongzhen Lan
Journal:  Tumour Biol       Date:  2015-02-09

Review 2.  The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis.

Authors:  Yaqin Tu; Cai Chen; Junru Pan; Junfa Xu; Zhi-Guang Zhou; Cong-Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

3.  Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Authors:  Lei Shi; Siqing Wang; Maurizio Zangari; Hongwei Xu; Thai M Cao; Chunjiao Xu; Yong Wu; Fang Xiao; Yinghong Liu; Ye Yang; Mohamed Salama; Guiyuan Li; Guido Tricot; Fenghuang Zhan
Journal:  Oncotarget       Date:  2010-05

4.  Epidermal growth factor upregulates Skp2/Cks1 and p27(kip1) in human extrahepatic cholangiocarcinoma cells.

Authors:  Ja-Yeon Kim; Hong Joo Kim; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Dong Hoon Kim; Seoung Wan Chae; Jin Hee Sohn
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

5.  Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death.

Authors:  Yongsheng Lan; Yongyou Zhang; Jianghua Wang; Chunhong Lin; Michael M Ittmann; Fen Wang
Journal:  Int J Cancer       Date:  2008-08-01       Impact factor: 7.396

6.  PADI3 plays an antitumor role via the Hsp90/CKS1 pathway in colon cancer.

Authors:  Zhengbin Chai; Li Wang; Yabing Zheng; Na Liang; Xiwei Wang; Yingying Zheng; Zhiwei Zhang; Chuanxi Zhao; Tingting Zhu; Chunyan Liu
Journal:  Cancer Cell Int       Date:  2019-11-05       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.